Komori
Fuji Pharma (4554) · RiskRestated

Risk of Product Supply Delays or Suspension Due to Shutdowns at Manufacturing Facilities and Warehouses

First written in FY2017. 2 of 4 entries say "Restated". Latest entry: FY2022.

4entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017MitigatedFY2020RestatedFY2021 – FY20222017: 12018: 020182019: 020192020: 120202021: 120212022: 12022
Same theme, other companies

The whole theme swung hardest in 2018: 32 of 131 companies on the "Worse" side.

90 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 187 companies compared. The sentences above are computed from all 187.Comparing 200 of the theme's 501 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2022RestatedAnnual report

    「As a measure, we have established an internal Risk Management Committee and are preparing alternative supply plans and supply recovery procedures for use in the event of a disaster.」

    Continues to maintain alternative supply plans and recovery procedures as measures against supply risks arising from the shutdown of manufacturing facilities and warehouses.
  2. FY2021RestatedAnnual report

    「As a measure, we have established an internal Risk Management Committee and are preparing alternative supply plans and supply recovery procedures for use in the event of a disaster.」

    Continues to describe the supply risk arising from the shutdown of manufacturing facilities and warehouses and the measures involving alternative supply plans and recovery procedures.
  3. FY2020MitigatedAnnual report

    「As a measure, we have established an internal Risk Management Committee and are preparing alternative supply plans and supply recovery procedures for use in the event of a disaster.」

    Describes the response to the risk of manufacturing facilities and warehouses being shut down, namely the preparation of alternative supply plans and recovery procedures.
  4. FY2017First statedAnnual report

    「If operations at manufacturing facilities, warehouses or other sites used to manufacture products are suspended or disrupted due to technical or regulatory problems, fires, earthquakes or other man-made or natural disasters, supply of the relevant products may be suspended, affecting the Group's business performance.」

    The suspension of product supply due to shutdowns or disruptions at manufacturing facilities and warehouses is stated separately from the risk to stable supply across the generic market as a whole.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuji Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Product Supply Delays or Suspension Due to Shutdowns at Manufacturing Facilities and Warehouses | Fuji Pharma Co.,Ltd. (4554) | Komori